Tetanus Vaccine Allergy: Arthus Reactions, Anaphylaxis & Desensitization

An Arthus reaction is a Type III immune-complex hypersensitivity that occurs in patients who already have very high anti-tetanus IgG antibody titers from too-frequent boosters. Four to twelve hours after injection, pre-existing antibody binds freshly injected toxoid, activates complement, and recruits neutrophils at the injection site, producing dramatic arm swelling, bruising, and deep pain. It is not anaphylaxis and not a lifetime contraindication. The CDC and ACIP recommend deferring the next tetanus-containing dose for at least 10 years rather than permanently avoiding the vaccine.

True tetanus vaccine anaphylaxis occurs in approximately one in 100,000 to one in a million doses, depending on the surveillance system. The CDC Vaccine Safety Datalink study by McNeil and colleagues, published in JACI in 2016, reviewed 25.17 million doses and found an overall vaccine anaphylaxis rate of 1.31 per million — with tetanus-containing products contributing disproportionately. The Institute of Medicine has concluded that evidence supports a causal relationship between tetanus-containing vaccines and anaphylaxis. This makes tetanus the most anaphylaxis-prone member of the DTaP, Tdap, and Td family.

It depends on what kind of reaction you had. Arthus-type reactions allow future tetanus dosing after a 10-year interval per ACIP. True IgE-mediated anaphylaxis requires allergist evaluation, skin testing, and if the vaccine is medically necessary, graded-dose desensitization rather than routine re-administration. A persistent itchy lump at the injection site suggests Type IV sensitivity to the aluminum adjuvant and does not preclude future tetanus vaccination. Vasovagal syncope during a previous visit is not an allergy at all and requires no special precautions beyond lying down during the next injection.

The tetanus toxoid protein itself is the usual culprit in true IgE-mediated anaphylaxis, which is unusual among vaccines where excipients like gelatin or yeast cause most reactions. Trace components of modern DTaP, Tdap, and Td products include formaldehyde residue from inactivation, aluminum hydroxide or phosphate adjuvant, 2-phenoxyethanol in Adacel and Daptacel, glutaraldehyde in Adacel, and polysorbate 80 in Boostrix and Infanrix. No egg, gelatin, yeast, neomycin, or latex appears in modern US tetanus-containing products. Aluminum is a common cause of delayed Type IV granulomas but not of anaphylaxis.

The AAAAI vaccine allergy practice parameter 9-step protocol administers incremental dilutions of tetanus toxoid — typically starting at a 1:1000 dilution, advancing through 1:100 and 1:10, then full strength — with 15 to 30 minute intervals between doses and vital signs monitored throughout. The full protocol takes four to eight hours in an allergy office or hospital setting with IV access and epinephrine immediately available. Desensitization provides temporary tolerance for that single exposure only; the underlying allergy persists and the protocol must be repeated for each subsequent tetanus-containing vaccine need.

Pregnancy itself does not add any allergy contraindication to Tdap, which is recommended between 27 and 36 weeks of every pregnancy to transfer protective antibody to the newborn before birth. If you have a history of severe reaction to a prior tetanus dose, the ideal workflow is preconception allergist evaluation so that any needed graded-dose desensitization can be planned electively rather than urgently during the third trimester. An Arthus reaction outside the 10-year window does not contraindicate pregnancy Tdap. Confirmed IgE anaphylaxis requires allergist-supervised desensitization if the vaccine is still indicated.

MenQuadfi is one of the newer meningococcal ACWY conjugate vaccines, and it uses tetanus toxoid as its polysaccharide carrier protein. Patients with confirmed IgE-mediated anaphylaxis to tetanus toxoid carry a real cross-reactivity risk because they are receiving the same allergen in a different vaccine. Alternative MenACWY products remain fully available: Menveo uses CRM197, a non-toxic mutant diphtheria toxin, as its carrier, and Menactra uses diphtheria toxoid. Your allergist and vaccinating clinician should cross-check meningococcal product selection whenever tetanus toxoid allergy is on your problem list.

Vasovagal syncope is an autonomic fainting episode that occurs during or immediately after injection, with pallor, cold clammy skin, bradycardia (slow heart rate), and rapid recovery within one to two minutes of lying supine. Anaphylaxis typically begins 5 to 30 minutes after injection and includes warm flushed skin, urticaria, angioedema, tachycardia, wheezing, and sustained hypotension that does not resolve with positioning alone. Serum tryptase drawn 30 to 120 minutes after the event is elevated in anaphylaxis but normal in syncope, and is the key objective biomarker for accurate retrospective diagnosis.